FindTrial
Sign In

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B)

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B) - JACCRO CC-05/CC-06 AR B

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000024954
Enrollment
77
Registered
2016-11-24
Start date
2016-09-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

None listed

Sponsors

Japan Clinical Cancer Research Organization
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who were treated in JACCRO CC-05 study (UMIN000004197) and in JACCRO CC-06 study (UMIN000007022) . (2) Patients who have the paraffin-embedded section of tumor tissue. (3) Approved to supply the sections for this research by IRB. (4) Obtained the informed consent from the patient, if in the case of death or disappearance, approval of IRB or the representative of hospital must be taken.

Exclusion criteria

Exclusion criteria: (1) Patients who are regarded as inadequate for study enrollment by investigators (2) Patients who refuse to supply the section

Design outcomes

Primary

MeasureTime frame
Correlation between the biomarkers and the response to cetuximab containing combination therapies.—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Research Organization Office

cc05cc06ar@jaccro.or.jp03-5579-9882

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026